Sugi Predict

Sugi Predict / Compounds / SCHEMBL1352192

SCHEMBL1352192

SCHEMBL1352192

Cc1cccc(C(N)C(N)=O)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.50
▸ ACP3 P15309 1/20 0.46
▸ ACHE P22303 2/20 0.41
▸ HTR3E A5X5Y0 1/20 0.40
▸ HTR3B O95264 1/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ HTR3D Q70Z44 1/20 0.40
▸ HTR3C Q8WXA8 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ TRPM8 Q7Z2W7 1/20 0.39
▸ AOC3 Q16853 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ SYK P43405 1/20 0.39
▸ DHODH Q02127 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20844696 1.00 PARP1 (0.50) PARP1ACP3ACHEHTR3EHTR3B
SCHEMBL1352191 1.00 PARP1 (0.50) PARP1ACP3ACHEHTR3EHTR3B
Hydrochloric Acid SCHEMBL28755174 0.98 PARP1 (0.48) PARP1ACP3ACHEHTR3EHTR3B
SCHEMBL8749833 0.85 HSD17B10 (0.50) PARP1ACP3TDP1HSD17B10CYP1A2
SCHEMBL5293096 0.85 HSD17B10 (0.50) PARP1ACP3TDP1HSD17B10CYP1A2
SCHEMBL28243743 0.85 HSD17B10 (0.50) PARP1ACP3TDP1HSD17B10CYP1A2
SCHEMBL9321541 0.84 PARP1 (0.53) PARP1ACP3ACHEHTR3EHTR3B
Hydrochloric Acid SCHEMBL28764410 0.83 HSD17B10 (0.49) PARP1ACP3TDP1HSD17B10CYP1A2
Hydrochloric Acid SCHEMBL19717652 0.83 HSD17B10 (0.49) PARP1ACP3TDP1HSD17B10CYP1A2
SCHEMBL28978915 0.81 PARP1 (0.47) PARP1ACP3ACHEHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 — — US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-8318755-B2 Inhibitors of SYK and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-11-27 — — US disclosed
WO-2012143144-A1 PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 — — WO disclosed
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 — — US disclosed
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-04-26 — — US disclosed
US-8063058-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-22 — — US disclosed
EP-2323993-A2 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS Portola Pharmaceuticals, Inc. (US) 2011-05-25 — — EP disclosed
US-20100048567-A1 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS INC. (US) 2010-02-25 — — US disclosed
WO-2009136995-A2 INHIBITORS OF SYK PROTEIN KINASE PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 PARP1 1789/4885ACP3 4035/4885ACHE 4148/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK PARP1 3745/4885ACP3 3620/4885ACHE 713/4885
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 PARP1 1789/4885ACP3 4035/4885ACHE 4148/4885
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 PARP1 1789/4885ACP3 4035/4885ACHE 4148/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 PARP1 3006/4885ACP3 4337/4885ACHE 2231/4885
US-20100048567-A1 Inhibitors of syk and JAK protein kinases SYK, BTK, JAK1 PARP1 1789/4885ACP3 4035/4885ACHE 4148/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PARP1 3557/4885ACP3 3501/4885ACHE 686/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PARP1 3557/4885ACP3 3501/4885ACHE 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.